BNTC
USDBenitec Biopharma Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$15.330
Haut
$15.770
Bas
$14.550
Volume
0.13M
Fondamentaux de l'Entreprise
Capitalisation Boursière
412.4M
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
0.05M
Bourse
NCM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma with a Buy and raises the price target from $28 to $35.
Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22
Citizens analyst Silvan Tuerkcan maintains Benitec Biopharma with a Market Outperform and raises the price target from $20 to $22.
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.